Spinomix formally announced the appointment of Pietro Scalfaro as Chief Executive Officer. This announcement builds on the momentum initiated earlier this year when Spinomix closed of a Series A equity investment of $3 million (USD).
Pietro has nearly 25 years of combined clinical practice and business acumen. Over the course of his 10-year tenure at Debiopharm, where he served as Chief Project Officer, Pietro led several successful drug development programs and implemented the Portfolio and Personalized Medicine Strategy – a streamlined approach covering all relevant pharmaceutical functions across 15 programs at different stages of development. Pietro has significant experience leading private equity investments for start-up molecular diagnostic companies focused on personalized medicine and has served on the boards of Agendia, Biocartis, Diagnoplex SA, and Immunexpress. Pietro holds an M.D. in gastroenterology and is a specialist in intensive care pediatrics. He received an executive Masters of Business Administration (MBA) in corporate finance from the University of Lausanne.